Effects of alprostadil on heart function and prognosis in patients with chronic congestive heart failure
XU Yao
XU Han
HAO Yun-xia
CUI Ai-dong
LIANG You-ling
YU Chun-ying
HU Ren-yue
LIU Ai-ling
Abstract：Objective To observe the improvement effect of alprostadil based on routine therapy for chronic congestive heart failure (CHF), and investigate further the risk factors influencing the prognosis in patients with CHF.Methods CHF patients (n=130, male 45, female 85, aged from 53 to 79, and average age=68.5±7.8) were chosen from May 2013 to Jun. 2014, and then randomly divided into control group and treatment group (each n=65). The control group was treated with routine anti-CHF drugs and treatment group was additionally treated with alprostadil (10 μg) once a day for 7 d. The changes of 6-minute walk test (6MWT), plasma N-terminal pro brain natriuretic peptide (NT-proBNP), hospitalization duration, left ventricular ejection fraction (LVEF), left ventricular fraction shortening (LVFS), left ventricular end-diastolic inner diameter (LVEDd) and left ventricular end-systolic diameter (LVESd) were compared in 2 groups before and after treatment. All patients were followed up for 120 d, and numbers of re-hospitalized cases due to progressive CHF and hospitalization duration were recorded.Results Compared with control group, 6MWD increased [(359.9±144.4) mvs. (414.9±145.1) m] and NT-proBNP decreased [(3120.0±1811.6) ng/Lvs. (2350.1±1731.1) ng/L] in treatment group (allP<0.05). The first time hospitalization duration was shorter in treatment group than that in control group [(11.2±2.6)vs. (12.3.±3.5),P<0.05]. After treatment, LVEF [(42.6±7.9)%vs. (45.7±7.7)%] and LVFS [(33.3±4.1)%vs. (35.1 ±4.3)%] increased and LVEDd decreased [(52.3±5.8) mmvs. (49.9±6.0) mm] in treatment group compared with control group (P<0.05). After followed up for 120 d, there were 26 cases re-hospitalized, and 15 in control group and 11 in treatment group. The interval between discharge and re-hospitalization was longer in treatment group than that in control group [(101.6±19.0)vs. (69.5±16.0),P<0.01]. The level of NT-proBNP (RR=7.395, 95%CI: 1.881~29.073) and COPD (RR=7.120, 95%CI: 2.762~18.349) were risk factors of progressive CHF. Theadministration of alprostadil based on routine therapy might improve the prognosis in CHF patients (RR=0.253, 95%CI: 0.096~0.666).Conclusion The administration of alprostadil based on routine therapy can further improve heart function and prognosis in CHF patients.
Keywords：AlprostadilHeart failureN-terminal pro brain natriuretic peptideHeart function
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 823-826,832 )